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Alu RNA accumulation due to DICER1 deficiency in
the retinal pigmented epithelium (RPE) is implicated
in geographic atrophy (GA), an advanced form
of age-related macular degeneration that causes
blindness in millions of individuals. The mechanism
of Alu RNA-induced cytotoxicity is unknown. Here
we show that DICER1 deficit or Alu RNA exposure
activates the NLRP3 inflammasome and triggers
TLR-independent MyD88 signaling via IL18 in
the RPE. Genetic or pharmacological inhibition of
inflammasome components (NLRP3, Pycard, Cas-
pase-1), MyD88, or IL18 prevents RPE degeneration
induced by DICER1 loss or Alu RNA exposure. These
findings, coupled with our observation that human
GA RPE contains elevated amounts of NLRP3,
PYCARD, and IL18 and evidence of increased
Caspase-1 andMyD88 activation, provide a rationale
for targeting this pathway in GA. Our findings also
reveal a function of the inflammasome outside theimmune system and an immunomodulatory action
of mobile elements.INTRODUCTION
Age-related macular degeneration (AMD) affects the vision of
millions of individuals (Smith et al., 2001). AMD is characterized
by degeneration of the retinal pigmented epithelium (RPE), which
is situated between the retinal photoreceptors and the choroidal
capillaries (Ambati et al., 2003). RPE dysfunction disrupts both
photoreceptors and choroidal vasculature (Blaauwgeers et al.,
1999; Lopez et al., 1996; McLeod et al., 2009; Vogt et al.,
2011). These tissue disruptions lead to atrophic or neovascular
disease phenotypes. Although there are therapies for neovascu-
lar AMD, there is no effective treatment for the more common
atrophic form. Geographic atrophy (GA), the advanced stage of
atrophic AMD, is characterized by degeneration of the RPE
and is the leading cause of untreatable vision loss.
Recently we showed that a dramatic and specific reduction of
the RNase DICER1 leads to accumulation of Alu RNA transcripts
in the RPE of human eyes with GA (Kaneko et al., 2011). These
repetitive element transcripts, which are noncoding RNAsCell 149, 847–859, May 11, 2012 ª2012 Elsevier Inc. 847
Figure 1. Alu RNA Does Not Activate or Function via TLRs
(A–E) pAlu, but not pNull, induces RPE degeneration inWT (A), Tlr3/mice (B),
Tlr7/ mice (C), Unc93b1 mtmice, which are functionally deficient in TLRs 3,
7, 9 (D), and Tlr4/mice (E). Representative images shown. n = 8–12. Fundus
photographs, top row; flat mounts stained for zonula occludens-1 (ZO-1; red),
bottom row. Degeneration outlined by blue arrowheads. Scale bars, 20 mm.
(F) Stimulation of HEK293 cell lines expressing various TLRs with either of two
different Alu RNA sequences does not elicit NF-kB activation. Positive (+)
controls using TLR-specific ligands activated NF-kB. n = 3.
See also Figure S1.expressed by the highly abundant Alu retrotransposon (Batzer
and Deininger, 2002), induce human RPE cell death and RPE
degeneration in mice. DICER1 deficit in GA RPE was not
a generic cell-death response because DICER1 expression
was not dysregulated in other retinal diseases. Likewise, Alu
RNA accumulation did not represent generalized retrotranspo-
son activation due to a stress response in dying cells because
other retrotransposons were not elevated in GA RPE.
DICER1 is central to mature microRNA (miRNA) biogenesis
(Bernstein et al., 2001). Yet following DICER1 deficit, the accu-
mulation of Alu RNA and not the lack of mature miRNAs was848 Cell 149, 847–859, May 11, 2012 ª2012 Elsevier Inc.the critical determinant of RPE cell viability (Kaneko et al.,
2011). Moreover, 7SL RNA, transfer RNA, and primary miRNAs
do not induce RPE degeneration (Kaneko et al., 2011), ruling
out a nonspecific toxicity of excess, highly structured RNA.
Still, the precise mechanisms of Alu RNA cytotoxicity are
unknown.
Although the retina is exceptional for its immune privilege
(Streilein, 2003), insults mediated by innate immune sensors
can result in profound inflammation. The three major classes of
innate immune receptors include the toll-like receptors (TLRs),
RIG-I-like helicases, and NLR proteins (Akira et al., 2006).
Numerous innate immune receptors are expressed in the RPE
(Kumar et al., 2004), and several exogenous substances can
induce retinal inflammation (Allensworth et al., 2011; Kleinman
et al., 2012). However, it is not known whether this surveillance
machinery recognizes or responds to host endogenous RNAs.
We explored the concept that innate immune machinery, whose
canonical function is the detection of pathogen-associated
molecular patterns and other moieties from foreign organisms,
might also recognize Alu RNA.
Indeed, we show that Alu transcripts can hijack innate immu-
nity machinery to induce RPE cell death. Surprisingly, our data
show that DICER1 deficit orAluRNA activates the NLRP3 inflam-
masome in a MyD88-dependent but TLR-independent manner.
NLRP3 inflammasome activation in vivo has been largely
restricted to immune cells, although our data open up the possi-
bility that NLRP3 activity may be more widespread, as reflected
by examples in cell culture studies of keratinocytes (Feldmeyer
et al., 2007; Keller et al., 2008). Our data also broaden the scope
of DICER1 function beyond miRNA biogenesis and identify
DICER1 as a guardian against aberrant accumulation of toxic
retrotransposon elements that comprise roughly 50% of the
human genome (Lander et al., 2001). In sum, our findings present
a novel self-recognition immune response, whereby endoge-
nous noncoding RNA-induced NLRP3 inflammasome activation
results from DICER1 deficiency in a nonimmune cell.
RESULTS
Alu RNA Does Not Activate a Variety of TLRs or RNA
Sensors
Alu RNA has single-stranded (ss) RNA and double-stranded (ds)
RNA motifs (Sinnett et al., 1991). Thus we tested whether Alu
RNA induced RPE degeneration in mice deficient in TLR3, a
dsRNA sensor (Alexopoulou et al., 2001), or TLR7, a ssRNA
sensor (Diebold et al., 2004; Heil et al., 2004). Subretinal delivery
of a plasmid coding for Alu RNA (pAlu) induced RPE degenera-
tion in Tlr3/ and Tlr7/ mice just as in wild-type (WT) mice
(Figures 1A–1C). We previously showed that R21-nucleotide
fully complementary small interfering RNAs (siRNAs) activate
TLR3 on RPE cells (Kleinman et al., 2012). Lack of TLR3 activa-
tion by Alu RNA is likely due to its complex structure containing
multiple hairpins and bulges that might preclude TLR3 binding.
Neither 7SL RNA, the evolutionary precursor of Alu RNA, nor
p7SL induced RPE degeneration in WT mice (Figures S1A and
S1B available online), suggesting thatAluRNA cytotoxicity might
be due to as yet unclear structural features. pAlu induced RPE
degeneration in Unc93b1 mice (Figure 1D), which lack TLR3,
TLR7, and TLR9 signaling (Tabeta et al., 2006), indicating that
these nucleic acid sensors are not activated by Alu RNA redun-
dantly. pAlu induced RPE degeneration in Tlr4/ mice (Fig-
ure 1E), and the TLR4 antagonist Rhodobacter sphaeroides
LPS (Qureshi et al., 1991) did not inhibit pAlu-induced RPE
degeneration in WT mice (Figure S1C). Thus the observed RPE
cell death is not due to lipopolysaccharide contamination.
Further, two different in vitro transcribed Alu RNAs (Kaneko
et al., 2011) did not activate multiple TLRs (Figure 1F).
Next we tested whether other dsRNA sensors such as MDA5
(Kato et al., 2006) or PKR (encoded by Prkr; Yang et al., 1995)
might mediate Alu RNA toxicity. However, pAlu induced RPE
degeneration in Mda5/ and Prkr/ mice (Figures S1D and
S1E). We tested whether the 50-triphosphate on in vitro tran-
scribed Alu RNA, which could activate RIG-I or IFIT-1 that sense
this moiety (Hornung et al., 2006; Pichlmair et al., 2011), was
responsible for RPE degeneration. Dephosphorylated Alu RNA
induced RPE degeneration in WT mice just as well as Alu RNA
not subjected to dephosphorylation (Figure S1F), indicating
that this chemical group is not responsible for the observed
cell death. Indeed a 50-triphosphate ssRNA that activates RIG-I
does not induce RPE degeneration in mice (Kleinman et al.,
2012). Further, pAlu induced RPE degeneration in mice deficient
in mitochondrial antiviral signaling (MAVS) (Figure S1G), through
which RIG-I and MDA-5 signal (Kumar et al., 2006; Sun et al.,
2006). Collectively these data pointed to an unforeseen mecha-
nism of Alu RNA-induced RPE degeneration not mediated by
a wide range of canonical RNA sensors.
Alu RNA Cytotoxicity Is Mediated via MyD88 and IL18
We then tested the involvement of TRIF (encoded by Ticam1), an
adaptor for TLR3 and TLR4 (Hoebe et al., 2003; Yamamoto et al.,
2003), and MyD88, an adaptor for all TLRs except TLR3 (Akira
et al., 2006; Alexopoulou et al., 2001; Suzuki et al., 2003). Alu
RNA induced RPE degeneration in Ticam1/mice (Figure S2A),
consistent with findings in Tlr3/ and Tlr4/ mice. Unexpect-
edly, neither Alu RNA nor two different pAlu plasmids induced
RPE degeneration in Myd88/ mice (Figures 2A, S2B, and
S2C). Intravitreous delivery of a peptide inhibitor of MyD88
homodimerization (Loiarro et al., 2005) prevented RPE degener-
ation induced by Alu RNA in WTmice, whereas a control peptide
did not do so (Figure 2B). A MyD88-targeting siRNA, which was
shorter than 21 nucleotides in length to prevent TLR3 activation
and conjugated to cholesterol to enable cell permeation (Klein-
man et al., 2008), but not a control siRNA inhibited RPE degen-
eration induced by pAlu in WT mice (Figures 2C–2E). Myd88+/
heterozygous mice were protected against Alu RNA-induced
RPE degeneration (Figures 2F and S2D), corroborating the
siRNA studies that partial knockdown of MyD88 is therapeuti-
cally sufficient.
MyD88-mediated signal transduction induced by interleukins
leads to recruitment and phosphorylation of IRAK1 and IRAK4
(Cao et al., 1996; Kanakaraj et al., 1999; Suzuki et al., 2002,
2003). Alu RNA increased IRAK1/4 phosphorylation in human
RPE cells (Figure 2G), supporting the concept that Alu RNA trig-
gers MyD88 signaling. The MyD88 inhibitory peptide reduced
Alu RNA-induced IRAK1/4 phosphorylation in human RPE cells
(Figure S2E), confirming its mode of action.Next we assessed whether MyD88 activation mediates Alu
RNA-induced cell death in human and mouse RPE cell culture
systems. Consonant with the in vivo data, pAlu reduced cell
viability in WT but not Myd88/ mouse RPE cells (Figure 2H).
The MyD88-inhibitory peptide, but not a control peptide, in-
hibited cell death in human RPE cells transfected with pAlu (Fig-
ure 2I). Together, these data indicate that MyD88 is a critical
mediator of Alu RNA-induced RPE degeneration.
MyD88 is generally considered an adaptor of immune cells
(O’Neill and Bowie, 2007). However, Alu RNA induced cell death
via MyD88 in RPE monoculture. Thus, we tested whether Alu
RNA-induced RPE degeneration in mice was also dependent
solely on MyD88 activation in RPE cells. Conditional ablation of
MyD88 in the RPE by subretinal injection of AAV1-BEST1-Cre
in Myd88f/f mice protected against Alu RNA-induced RPE
degeneration (Figures 2J and S2F). Consistent with this finding,
Alu RNA induced RPE degeneration in WT mice receiving
Myd88/ bone marrow but did not do so in Myd88/ mice
receiving WT bone marrow (Figure S2G). Collectively, these
results indicate that MyD88 expression in the RPE, and not in
circulating immune cells, is critical for Alu RNA-induced RPE
degeneration. These findings comport with histopathological
studies of human GA tissue that show no infiltration of immune
cells in the area of pathology (C.A. Curcio, H.E. Grossniklaus,
G.S. Hageman, and L.V. Johnson, personal communication).
Although MyD88 is critical in TLR signaling (O’Neill and Bowie,
2007), MyD88 activation by Alu RNA was independent of TLR
activation. Thus, we examined other mechanisms of MyD88
involvement. MyD88 can regulate IFN-g signaling by interacting
with IFN-g receptor 1 (encoded by Ifngr1) (Sun and Ding, 2006).
However, pAlu induced RPE degeneration in both Ifng/ and
Ifngr1/ mice (Figures S2H and S2I). MyD88 is also essential
in interleukin-1 signaling (Muzio et al., 1997). Thus, we tested
whether IL1b and the related cytokine IL18, both of which acti-
vateMyD88 (Adachi et al., 1998), mediated AluRNA cytotoxicity.
Interestingly, whereas Alu RNA overexpression in human RPE
cells increased IL18 secretion, IL1b secretion was barely detect-
able (Figure 2K).
Recombinant IL18 induced RPE degeneration in WT but not
Myd88/mice (Figure 2L). IL18 neutralization protected against
pAlu-induced RPE degeneration in WT mice, but IL1b did not
(Figures 2M and 2N). Also, pAlu induced RPE degeneration in
Il1r1/ mice but not Il18r1/ mice (Figures S2J and S2K).
These data indicate that IL18 is an effector of Alu RNA-induced
cytotoxicity.
Alu RNA Activates the NLRP3 Inflammasome
We explored whether Caspase-1 (encoded by Casp1),
a protease that induces maturation of interleukins into biologi-
cally active forms (Ghayur et al., 1997; Gu et al., 1997; Thorn-
berry et al., 1992), was involved in Alu RNA-induced RPE degen-
eration. Alu RNA treatment of human RPE cells led to Caspase-1
activation as measured by western blotting and by a fluorescent
reporter of substrate cleavage (Figures 3A and S3A). Indeed, Alu
RNA induced Caspase-1 activation in other cell types such as
HeLa and THP-1 monocytic cells (Figure S3B), suggesting that
Alu RNA cytotoxicity has potentially broad implications in many
systems. Intravitreous delivery of the Caspase-1-inhibitoryCell 149, 847–859, May 11, 2012 ª2012 Elsevier Inc. 849
Figure 2. Alu RNA Induces RPE Degeneration via MyD88
(A) pAlu does not induce RPE degeneration in Myd88/ mice.
(B) pAlu-induced RPE degeneration in WT mice is inhibited by a MyD88 homodimerization peptide inhibitor (MyD88i), but not by a control peptide.
(C) pAlu-induced RPE degeneration in WT mice is inhibited by cholesterol-conjugated Myd88 siRNA but not control siRNA.
(D and E) siRNA targetingMyD88 (siMyD88) reduces target gene (D) and protein (E) abundance inmouse RPE cells compared to control siRNA. n = 3, *p < 0.05 by
Student’s t test.
(F) pAlu does not induce RPE degeneration in Myd88 heterozygous (het) mice.
(G) Western blot of Alu RNA-induced IRAK1 and IRAK4 phosphorylation in human RPE cells. Image representative of three experiments.
(H) pAlu reduces cell viability of WT but not Myd88/ mouse RPE cells.
(I) Loss of human RPE cell viability induced by pAlu is rescued by MyD88i.
(J) AAV1-BEST1-Cre, but not AAV1-BEST1-GFP, protected Myd88f/f mice from pAlu-induced RPE degeneration.
(K) pAlu induces IL18 secretion from human RPE cells measured by ELISA. IL1b secretion is barely detectable. n = 3, *p < 0.05 by Student’s t test.
850 Cell 149, 847–859, May 11, 2012 ª2012 Elsevier Inc.
Figure 3. Alu RNA Induces RPE Degeneration via NLRP3 Inflammasome
(A) Western blot of Caspase-1 activation (p20 subunit) by Alu RNA in human RPE cells.
(B) Western blot of pAlu-induced IL18 maturation in RPE cell lysates in WT mice impaired by Caspase-1 peptide inhibitor.
(C) Caspase-1 peptide inhibitor protects WT mice from pAlu-induced RPE degeneration.
(D and E) pAlu does not induce (D) RPE degeneration in Casp1/ mice or (E) cytotoxicity in Casp1/ mouse RPE cells.
(F) Alu RNA and LPS+ATP induce formation of PYCARD clusters in human RPE cells transfected with GFP-PYCARD.
(G and H) pAlu does not induce RPE degeneration in Nlrp3/ (G) or Pycard/ (H) mice.
(I) Nlrp3/ and Pycard/ mouse RPE cells are protected against pAlu-induced loss of cell viability.
(J) siRNAs targeting NLRP3 or PYCARD rescued human RPE cells from pAlu-induced cytotoxicity, compared to control siRNA.
n = 3–4, *p < 0.05 by Student’s t test (F and J). Data are represented as mean ± SEM (E, F, I, and G). Images representative of three experiments. Densitometry
values normalized to Vinculin are shown in parentheses (A and B). Fundus photographs, top row; ZO-1-stained (red) flat mounts, bottom row. Degeneration
outlined by blue arrowheads. n = 8–12. Scale bars, 20 mm (C, D, G, and H). Representative images shown. See also Figure S3.peptide Z-WEHD-FMK, but not a control peptide Z-FA-FMK,
blocked IL18 maturation and pAlu-induced RPE degeneration
in WT mice (Figures 3B and 3C). The Caspase-1-inhibitory
peptide blocked Alu RNA-induced substrate cleavage in human(L) Recombinant IL18 induces RPE degeneration in WT but not Myd88/ mice.
(M and N) pAlu-induced RPE degeneration in WT mice is rescued by IL18-neutra
Representative images shown. n = 8–12. Fundus photographs, top row; ZO-1-sta
Scale bars, 20 mm (A–C, F, J, and L–N). n = 3, *p < 0.05 by Student’s t test. Data
See also Figure S2.RPE cells (Figure S3C), confirming its mode of action. Similarly,
Casp1/ mice treated with Alu RNA or pAlu did not exhibit
RPE degeneration (Figures 3D and S3D). Also, pAlu did not
induce cell death in Casp1/ mouse RPE cells (Figure 3E).lizing antibody (N) but not by IL1b-neutralizing antibody (M).
ined (red) flat mounts, bottom row. Degeneration outlined by blue arrowheads.
are represented as mean ± SEM (D, H, I, and K).
Cell 149, 847–859, May 11, 2012 ª2012 Elsevier Inc. 851
Caspase-1 can be activated within a multiprotein innate
immune complex termed the inflammasome (Tschopp et al.,
2003). The best characterized inflammasome pathway is one
that is activated by binding of NLRP3 to the Caspase-1 adaptor
ASC (encoded by PYCARD). One hallmark of inflammasome
assembly is spatial clustering of PYCARD (Fernandes-Alnemri
et al., 2007). In human RPE cells transfected with fluorescent-
tagged PYCARD (GFP-PYCARD), Alu RNA induced the appear-
ance of a brightly fluorescent cytoplasmic cluster, similar to the
effect of treatment with LPS and ATP, which activates the
NLRP3 inflammasome (Figures 3F and S3E) (Mariathasan
et al., 2006).
Next we tested the functional relevance of NLRP3 and
PYCARD to Alu RNA cytotoxicity. Neither pAlu nor Alu RNA
induced RPE degeneration in either Nlrp3/ or Pycard/
mice (Figures 3G, 3H, S3F, and S3G), demonstrating the critical
importance of the inflammasome in Alu RNA cytotoxicity. Also,
pAlu did not induce cell death in Nlrp3/ or Pycard/ mouse
RPE cells (Figure 3I). Moreover, knockdown of NLRP3 or
PYCARD by siRNAs rescued pAlu-induced human RPE cell
death (Figures 3J and S3H). These findings provide direct
evidence that NLRP3 activation in response to Alu RNA occurs
in RPE cells and does not require the presence of other immune
cells.
We determined that IL18 and MyD88 activation indeed were
downstream of Caspase-1 activation by showing (1) that
although MyD88 inhibition reduced Alu RNA-induced IRAK1/4
phosphorylation in human RPE cells (Figure S2E), it did not
reduce Alu RNA-induced Caspase-1 cleavage or fluorescent
substrate cleavage (Figures S3I and S3J); (2) that IL18 neutraliza-
tion did not inhibit Alu RNA-induced Caspase-1 cleavage (Fig-
ure S3K); and (3) that Caspase-1 inhibition reduced Alu RNA-
induced phosphorylation of IRAK1/4 (Figure S3L).
Alu RNA Induces Mitochondrial ROS and NLRP3 Priming
NLRP3 inflammasome function requires two signals, the first of
which is termed priming. pAlu induced inflammasome priming
as it upregulated both NLRP3 and IL18 mRNAs. This priming
occurred equivalently in both WT and Myd88/ mouse RPE
cells (Figure 4A), further corroborating that MyD88 functions
downstream of NLRP3 in this system. Akin to other inflamma-
some agonists that do not directly interact with NLRP3 (Tschopp
and Schroder, 2010), we did not observe a physical interaction
between Alu RNA and NLRP3 (Figure S4A). To determine how
Alu RNA primed the inflammasome, we studied whether it
induced reactive oxygen species (ROS) production, a signal for
priming (Bauernfeind et al., 2011; Nakahira et al., 2011). pAlu
induced ROS generation in human RPE cells (Figure 4B), and
the ROS inhibitor diphenyliodonium (DPI) blocked pAlu-induced
NLRP3 and IL18mRNA upregulation and Alu RNA-induced RPE
degeneration in WT mice (Figures 4C and 4D). As DPI blocks
mitochondrial ROS and phagosomal ROS (Li and Trush, 1998),
we tested which pathway was triggered because there is contro-
versy surrounding the source of ROS contributing to NLRP3
responses (Latz, 2010).
We used MitoSOX Red, which labels ROS-generating mito-
chondria, in combination with MitoTracker Deep Red, which
labels respiring mitochondria. To monitor phagosomal ROS852 Cell 149, 847–859, May 11, 2012 ª2012 Elsevier Inc.generation, we used Fc OxyBURST Green, which measures
activation of NADPH oxidase within the phagosome. A marked
increase in ROS-generating mitochondria was observed in
human RPE cells transfected with pAlu (Figure 4E). In contrast,
whereas phorbol myristate acetate (PMA) induced phagosomal
ROS as expected (Savina et al., 2006), pAlu did not do so (Fig-
ure 4F). These data are consistent with the findings that
NLRP3 responses are impaired by mitochondrial ROS inhibitors
(Nakahira et al., 2011; Zhou et al., 2011) but are preserved in cells
carrying genetic mutations that impair NADPH-oxidase-depen-
dent ROS production (Meissner et al., 2010; van Bruggen
et al., 2010).
Consonant with these reports and the observation that the
principal source of cellular ROS is mitochondria (Murphy,
2009), we found that the mitochondria-targeted antioxidants
Mito-TEMPO and MitoQ (Murphy and Smith, 2007; Nakahira
et al., 2011) both blocked Alu RNA-induced RPE degeneration
in WT mice, whereas dTPP, a structural analog of MitoQ that
does not scavengemitochondrial ROS, did not do so (Figure 4G).
In contrast, gp91 ds-tat, a cell-permeable peptide that inhibits
association of two essential NADPH oxidase subunits (gp91phox
and p47phox) (Rey et al., 2001), did not do so (Figure 4H). Corrob-
orating these data, Alu RNA induced RPE degeneration in mice
deficient in Cybb (which encodes gp91phox) just as in WT mice
(Figure 4I). Next we studied the voltage-dependent anion
channels (VDAC) because VDAC1 and VDAC2, but not VDAC3,
are important in mitochondrial ROS produced by NLRP3 activa-
tors in macrophages (Zhou et al., 2011). Consistent with
these observations, siRNA knockdown of VDAC1 and VDAC2,
but not VDAC3, impaired pAlu-induced mitochondrial ROS
(Figures 4J and S4B) and NLRP3 and IL18 mRNA induction in
human RPE cells (Figure 4K). Collectively, these data implicate
mitochondrial ROS in Alu RNA-induced NLRP3 inflammasome-
mediated RPE degeneration.
Alu RNA Does Not Induce RPE Degeneration via
Pyroptosis
Alu RNA activates Caspase-1, which can trigger pyroptosis,
a form of cell death characterized by formation of membrane
pores and osmotic lysis (Fink and Cookson, 2006). The cytopro-
tective agent glycine, which attenuates pyroptosis (Fink et al.,
2008; Fink and Cookson, 2006; Verhoef et al., 2005), inhibited
human RPE cell death induced by LPS+ATP but not by Alu
RNA (Figures 5A and 5B). Pyroptosis requires Caspase-1 but
can proceed independent of IL18 (Miao et al., 2010). Thus, our
finding that IL18 induced RPE degeneration in Casp1/ mice
(Figure 5C), coupled with the lack of rescue by glycine, suggests
that Alu RNA-induced RPE degeneration does not occur via
pyroptosis.
DICER1 Loss Induces Cell Death via Inflammasome
We previously demonstrated the key role of DICER1 in maintain-
ing RPE cell health (Kaneko et al., 2011): DICER1-cleaved Alu
RNA did not induce RPE degeneration in vivo; DICER1 overex-
pression protected against Alu RNA-induced RPE degeneration;
and DICER1 loss-induced RPE degeneration was blocked by
antagonizing Alu RNA (Kaneko et al., 2011). Also, rescue of
DICER1 knockdown-induced RPE degeneration by Alu RNA
Figure 4. Alu RNA Induces Mitochondrial ROS Production and NLRP3 Priming
(A) pAlu induces NLRP3 and IL18 mRNAs in WT and Myd88/ mouse RPE cells.
(B) pAlu induces generation of ROS in human RPE cells as monitored with the fluorescent probe H2DCFDA (A.U., arbitrary units).
(C) DPI blocks pAlu-induced NLRP3 and IL18 mRNAs in human RPE cells.
(D) DPI protects WT mice from pAlu-induced RPE degeneration.
(E) pAlu induces generation of mitochondrial ROS in human RPE cells as detected by the fluorescence of MitoSOX Red (green pseudocolor), colocalized with
respiring mitochondria labeled by MitoTracker Deep Red (red).
(F) PMA, but not pAlu, induces phagosomal ROS generation, as assessed by fluorescent Fc OXYBURST Green assay in human RPE cells (A.U., arbitrary units).
(G) MitoTempo and MitoQ, but not vehicle or dTPP controls, prevent Alu RNA-induced RPE degeneration in WT mice.
(H) NADPH oxidase inhibitor gp91 ds-tat or a scrambled peptide do not prevent Alu RNA-induced RPE degeneration in WT mice.
(I) Alu RNA induces RPE degeneration mice deficient in Cybb (which encodes the gp91phox subunit of NADPH oxidase).
(J and K) siRNAs targeting VDAC1 and VDAC2, but not VDAC3 or scrambled control, prevent pAlu-inducedmitochondrial ROS generation (J) and upregulation of
NLRP3 and IL18 mRNAs (K) in human RPE cells. Mitochondrial ROS visualized with MitoSox Red dye and cell nuclei with Hoechst stain.
n = 3–4, *p < 0.05 by Student’s t test (A–C, F, and K); NS, not significant by Student’s t test (F). Data are represented as mean ± SEM (A–C, F, and K). Repre-
sentative images shown; n = 8–12. ZO-1-stained (red) flat mounts. Scale bars, 20 mm (D, E, and G–I), n = 3–4. Scale bar, 100 mm (J). See also Figure S4.inhibition was not accompanied by restoration of miRNA
deficits (Kaneko et al., 2011). Therefore, we tested whether
DICER1 also prevented NLRP3 inflammasome activation byAlu RNA. Alu RNA-induced Caspase-1 activation in human
RPE cells was inhibited by DICER1 overexpression (Figures 6A
and 6B). Conversely, Caspase-1 cleavage induced by DICER1Cell 149, 847–859, May 11, 2012 ª2012 Elsevier Inc. 853
Figure 5. RPE Degeneration Does Not Occur via Pyroptosis
(A and B) Glycine inhibits human RPE cell death induced by LPS+ATP (A) but not by pAlu (B).
(C) Recombinant IL18 induces RPE degeneration in Casp1/ mice.
n = 3–4 (A and B), *p < 0.05 by Student’s t test. Data are represented asmean ±SEM (A and B). Representative images shown. n = 8–12. Fundus photographs, top
row; ZO-1-stained (red) flat mounts, bottom row. Degeneration outlined by blue arrowheads. Scale bars, 20 mm (C).knockdown in human RPE cells was inhibited by simultaneous
antisense knockdown of Alu RNA (Figures S5A and S5B).
Next we tested the relevance of these pathways in the context
of DICER1 loss in vivo. Caspase-1 cleavage was increased in the
RPE ofBEST1Cre;Dicer1f/f mice (Figure 6C), which lose DICER1
expression in the RPE during development and exhibit RPE
degeneration (Kaneko et al., 2011). Subretinal delivery of
AAV1-BEST1-Cre in Dicer1f/f mice induced Caspase-1 activa-
tion and IL18 maturation in the RPE (Figure 6D). This treatment
also induced RPE degeneration, which was blocked by intravit-
reous delivery of the Caspase-1-inhibitory peptide but not the
control peptide (Figure 6E). AAV1-BEST1-Cre-induced RPE
degeneration in Dicer1f/f mice was also blocked by intravitreous
delivery of the MyD88-inhibitory peptide but not a control
peptide (Figure 6F). In addition, MyD88 inhibition prevented
cell death in human RPE cells treated with antisense oligonucle-
otides targeting DICER1 (Figure 6G). DICER1 knockdown in
human RPE cells increased IRAK1/4 phosphorylation, providing
further evidence of MyD88 activation upon loss of DICER1 (Fig-
ure 6H). MyD88 inhibition also prevented cell death in Dicer1f/f
mouse RPE cells treated with an adenoviral vector coding for
Cre recombinase (Figure 6I). MyD88 inhibition blocked RPE
cell death without restoring the miRNA expression deficits
induced by Dicer1 knockdown (Figure 6J). These findings
demonstrate that DICER1 is an essential endogenous negative
regulator of NLRP3 inflammasome activation, and that DICER1
deficiency leads to Alu RNA-mediated, MyD88-dependent,
miRNA-independent RPE degeneration.
Inflammasome and MyD88 Activation in Human GA
Next we tested whether human eyes with GA, which exhibit loss
of DICER1 and accumulation of Alu RNA in their RPE (Kaneko
et al., 2011), also display evidence of inflammasome activation.
The abundance of NLRP3 mRNA in the RPE of human eyes
with GA was markedly increased compared to control eyes
(Figure 7A). IL18 and IL1BmRNA abundance also was increased
in GA RPE; however, only the disparity in IL18 levels reached854 Cell 149, 847–859, May 11, 2012 ª2012 Elsevier Inc.statistical significance (Figure 7A). Immunolocalization studies
showed that the expression of NLRP3, PYCARD, and
Caspase-1 proteins was also increased in GA RPE (Figures
7B–7D). Western blot analyses corroborated the increased
abundance of NLRP3 and PYCARD in GA RPE and revealed
greatly increased levels of the enzymatically active cleaved Cas-
pase-1 p20 subunit in GA RPE (Figure 7E). There was also an
increase in the abundance of phosphorylated IRAK1 and
IRAK4 in GA RPE, indicative of increased MyD88 signal trans-
duction (Figure 7E). Collectively, these data provide evidence
of NLRP3 inflammasome and MyD88 activation in situ in human
GA, mirroring the functional data in human RPE cell culture and
mice in vivo.
DISCUSSION
Our data establish a functional role for the subversion of innate
immune sensing pathways by Alu RNA in the pathogenesis of
GA. Collectively, our findings demonstrate that the NLRP3
inflammasome senses GA-associated Alu RNA danger signals
and contributes to RPE degeneration and potentially vision
loss in AMD (Figure S6). To date, the function of the NLRP3
inflammasome has been largely restricted to immune cells
in vivo. Our finding that it plays a critical function in RPE cell
survival broadens the cellular scope of this inflammasome and
raises the possibility that other nonimmune cells could employ
this platform.
The NLRP3 inflammasome was originally recognized as
a sensor of external danger signals such as microbial toxins
(Kanneganti et al., 2006; Mariathasan et al., 2006; Muruve
et al., 2008). Subsequently, endogenous crystals, polypeptides,
and lipids were reported to activate it in diseases such as gout,
atherogenesis, Alzheimer’s disease, and type 2 diabetes (Halle
et al., 2008; Masters et al., 2010; Muruve et al., 2008; Wen
et al., 2011). To our knowledge, Alu RNA is the first endogenous
nucleic acid known to activate this immune platform. Our find-
ings expand the diversity of endogenous danger signals in
Figure 6. DICER1 Loss Induces Cell Death via Inflammasome
(A) Western blot of Alu RNA-induced Caspase-1 cleavage (p20) inhibited by DICER1 overexpression in human RPE cells.
(B and C) DICER1 overexpression reduces Alu RNA-induced Caspase-1 activation in human RPE cells (measured by cleavage [B, left panel, green] of Caspalux1
fluorescent substrate). Fluorescence quantification shown in right panel.
(C) Western blot of increased Caspase-1 activation (p20 subunit) in RPE cell lysates of BEST1-Cre; Dicer1f/f mice compared to BEST1-Cre or Dicer1f/f mice.
(D) Western blot of increased Caspase-1 activation (p20 subunit) and IL18 maturation in RPE cell lysates of Dicer1f/f mice treated with AAV1-BEST1-Cre.
(E and F) RPE degeneration induced by AAV1-BEST1-Cre in Dicer1f/f mice is rescued by peptide inhibitors of either Caspase-1 (E) or MyD88 (F).
(G) MyD88 inhibitor rescues loss of human RPE cell viability induced by DICER1 antisense (AS) treatment.
(H) DICER1 antisense (AS) treatment of human RPE cells reduces DICER1 and increases IRAK1 and IRAK4 phosphorylation.
(I) MyD88 inhibitor rescues loss of cell viability in Dicer1f/f mouse RPE cells treated with adenoviral vector coding for Cre recombinase (Ad-Cre).
(J) Ad-Cre induced global miRNA expression deficits inDicer1f/f mouse RPE cells compared to Ad-Null. No significant difference was found in miRNA abundance
between MyD88 inhibitor and control peptide-treated Dicer1 depleted cells.
n = 3 (A, B, and F–H). Images are representative of three experiments (A, C, D, and H). Densitometry values normalized to Vinculin are shown in parentheses
(A andC). n = 3–4, *p < 0.05 by Student’s t test. Data are represented asmean ±SEM (B, G, and I). Representative images shown. n = 8–12. ZO-1-stained (red) flat
mounts. Scale bars, 20 mm (E and F). See also Figure S5.chronic human diseases and comport with the concept that this
inflammasome is a sensor of metabolic danger (Schroder et al.,
2010).Dampening inflammasome activation can be essential to
limiting the inflammatory response. Pathogens have evolved
many strategies to inhibit inflammasome activation (MartinonCell 149, 847–859, May 11, 2012 ª2012 Elsevier Inc. 855
Figure 7. NLRP3 Inflammasome and MyD88 Activation in Human GA
(A) NLRP3 and IL18 abundance was significantly elevated in macular GA RPE (n = 13) compared to normal age-matched controls (n = 12). *p < 0.05 by Mann-
Whitney U test. There was no significant difference between groups (p = 0.32 by Mann-Whitney U test) in IL1B abundance.
(B–D) Increased immunolocalization of NLRP3 (B), PYCARD (C), and Caspase-1 (D) in macular GA RPE compared to age-matched normal controls. Scale bars,
20 mm.
(E) Western blots of macular RPE lysates from individual human donor eyes show that abundance of NLRP3, PYCARD, and phosphorylated IRAK1/4, normalized
to the levels of the housekeeping protein Vinculin, is increased in GA compared to age-matched normal controls.
Data are represented as mean ± SEM (A). Representative images shown. n = 6 (B–E). See also Figure S6.et al., 2009). Likewise, host autophagy proteins (Nakahira et al.,
2011), type I interferon (Guarda et al., 2011), and T cell contact
with macrophages can inhibit this process (Guarda et al.,
2009). Our finding that DICER1, through its cleavage of Alu
RNA, prevents activation of NLRP3 adds to the repertoire of
host inflammasome modulation capabilities and reveals a new
facet of how dysregulation of homeostatic anti-inflammatory
mechanisms can promote AMD (Ambati et al., 2003; Takeda
et al., 2009).
Added to its recently described antiapoptotic and tumor-
related functions, DICER1 emerges as a multifaceted protein. It
remains to be determined how this functional versatility is chan-
neled in various states. As DICER1 dysregulation is increasingly
recognized in several human diseases, it is reasonable to
imagine that Alu RNA might be an inflammasome activating
danger signals in those conditions too. It is also interesting
that, at least in adult mice and in a variety of mouse and human
cells, the miRNA biogenesis function of DICER1 is not critical for
cell survival, at least in a MyD88-deficient environment (data not
shown).
Our data that mitochondrial ROS production is involved in Alu
RNA-induced RPE degeneration comport with observations of
mitochondrial DNA damage (Lin et al., 2011), downregulation
of proteins involved in mitochondrial energy production and traf-
ficking (Nordgaard et al., 2008), and reduction in the number and
size ofmitochondria (Feher et al., 2006) in the RPE of human eyes856 Cell 149, 847–859, May 11, 2012 ª2012 Elsevier Inc.with AMD. Jointly, these findings suggest a potential therapeutic
benefit to interfering with mitochondrial ROS generation.
Current clinical programs targeting the inflammasome largely
focus on IL1b; presently there are no IL18 inhibitors in registered
clinical trials. However, our data indicate that IL18 ismore impor-
tant than IL1b in mediating RPE cell death in GA (similar to selec-
tive IL18 involvement in a colitis model; Zaki et al., 2010), pointing
to the existence of regulatory mechanisms by which inflamma-
some activation bifurcates at the level of or just preceding the
interleukin effectors. Although Caspase-1 inhibition could be
an attractive local therapeutic strategy, caspase inhibitors can
promote alternative cell death pathways, possibly limiting their
utility (Vandenabeele et al., 2006).
MyD88 is best known for transducing TLR signaling initiated
by pathogen-associated molecular patterns (O’Neill and Bowie,
2007), although recently it has been implicated in human cancers
(Ngo et al., 2011; Puente et al., 2011). Our findings introduce an
unexpected function for MyD88 in effecting death signals from
mobile element transcripts that can lead to retinal degeneration
and blindness and raise the possibility that MyD88 could be
a central integrator of signals from other non-NLRP3 inflamma-
somes that also employ Caspase-1 (Schroder and Tschopp,
2010). Because noncanonical activation of MyD88 is a critical
checkpoint in RPE degeneration in GA (Figure S6), it represents
an enticing therapeutic target. A potential concern is its impor-
tant antimicrobial function in mice (O’Neill and Bowie, 2007).
However, in contrast to Myd88/ mice, adult humans with
MyD88 deficiency are described to be generally healthy and
resistant to a wide variety of microbial pathogens (von Bernuth
et al., 2008). MyD88-deficient humans have a narrow suscepti-
bility range to pyogenic bacterial infections, and that too only
in early childhood and not adult life (Picard et al., 2010). More-
over, as evident from the siRNA and Myd88+/ studies, partial
inhibition of MyD88 is sufficient to protect against Alu RNA.
Localized intraocular therapy, the current standard of care in
most retinal diseases, would further limit the likelihood of
adverse infectious outcomes. It is reasonable to foresee devel-
opment of MyD88 inhibitors for prevention or treatment of GA.
EXPERIMENTAL PROCEDURES
A detailed description of materials and methods can be found in the Extended
Experimental Procedures.
Subretinal Injection and Imaging
Subretinal injections (1 ml) were performed using a Pico-Injector (PLI-100,
Harvard Apparatus). Plasmids were transfected in vivo using 10%Neuroporter
(Genlantis). Fundus imaging was performed on a TRC-50 IX camera (Topcon)
linked to a digital imaging system (Sony). RPE flat mounts were immunola-
beled using antibodies against zonula occludens-1 (Invitrogen).
Cell Viability
Cell viability was assessed using CellTiter 96 AQueousOne Solution Cell Prolif-
eration Assay (Promega) according to manufacturer’s instructions.
mRNA Abundance
Transcript abundance was quantified by real-time RT-PCR using an Applied
Biosystems 7900 HT Fast Real-Time PCR system by the 2DDCt method.
Protein Abundance and Activity
Protein abundance was assessed by western blot analysis using antibodies
against Caspase-1 (1:500; Invitrogen), pIRAK1 (1:500, Thermo Scientific),
pIRAK4 (1:500, Abbomax), PYCARD (1:200, Santa Cruz Biotechnology),
NLRP3 (1:500, Enzo Life Sciences), and Vinculin (1:1,000, Sigma-Aldrich).
Caspase-1 activity was visualized using Caspalux1 E1D2 (OncoImmunin)
according to manufacturer’s instructions.
Statistical Analysis
Results are expressed as mean ± standard error of the mean (SEM), with
p values < 0.05 considered statistically significant. Differences between
groups were compared by Mann-Whitney U test or Student’s t test, as appro-
priate, and two-tailed p values are reported.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures and
six figures and can be found with this article online at doi:10.1016/j.cell.
2012.03.036.
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